Overview

Evaluation of Weekly Tafenoquine

Status:
Completed

Trial end date:
1998-09-01

Target enrollment:

Participant gender:

Summary

This study is a phase 2b, placebo controlled, randomized, blinded study of the efficacy of WR 238605, a new primaquine analog, compared to placebo as chemosuppression of P. falciparum malaria in Nyanza Province, western Kenya.

Phase:

Phase 2

Details

Lead Sponsor:

U.S. Army Medical Research and Development Command
U.S. Army Medical Research and Materiel Command

Collaborator:

SmithKline Beecham

Treatments:

Tafenoquine